The pathogen was identified in 63 patients aged≥15 years with acute bacterial sinusitis who visited this clinic during the 4-month period from February 1, 2006. In addition, the sensitivity of 4 bacterial species including
H. influenzae and
S. pneumoniae to 8 antimicrobials were evaluated. The severity of the disease was classified based on the clinical findings and intranasal findings before treatment. The clinical effects of gatifloxacin (GFLX) were evaluated based on changes in severity after its administration. Seventy-four bacterial strains were detected in 58 patients:
H. influenzae, 17.6%;
S. pneumoniae, 16.2%;
M. catarrhalis, 9.5%; and
S. aureus, 9.5%. Antimicrobial testing showed that 61.5% of
H. influenzae strains were resistant to ampicillin while 41.7% and 16.7% of
S. pneumoniae strains were penicillin-intermediately resistant
S. pneumoniae (PISP) and penicillin resistant
S. pneumoniae (PRSP), respectively. Even these resistant strains showed no resistance to GFLX, and GFLX was effective in 88.7%. The results of the
in vitro examination and clinical effects in this study suggested the usefulness of GFLX for the treatment of acute bacterial sinusitis.
View full abstract